Astellas Looks Up In 2010; Eisai Draws Growth From Domestic And Chinese Markets: Japanese Pharma Earnings Roundup (Part 1 Of 2)

Major Japanese pharmas face many of the same problems as major Western pharmas, including patent cliffs and growth slowdown in traditional markets. Japanese pharmas, on the other hand, have been slower to establish themselves in emerging markets. But that may soon be changing, as can be seen in this Japanese pharma earnings roundup, a periodic feature in PharmAsia News.